TRPV1 and Alzheimer disease: Notably, TRPV1 antagonist capsazepine (CPZ, 1 mg/kg, i.p.)administration did not affect the escape latency for searching for the hidden platform in both WT (WT + CPZ: n = 7; 74.71 ± 5.84 s on Day 1, 65.80 ± 15.18 s on Day 2, 47.48 ± 11.07 s on Day 3, 35.58 ± 10.42 s on Day 4, 38.67 ± 9.09 s on Day 5; p = .275 vs. WT; Figure 6a) and APP23/PS45 mice (AD + CPZ: n = 8; 80.87 ± 9.56 s on Day 1, 81.06 ± 8.89 s on Day 2, 74.81 ± 12.38 s on Day 3, 62.55 ± 9.71 s on Day 4, 56.66 ± 5.91 s on Day 5; p = .100 vs. AD; Figure 6a), compared to vehicle treatment.